Cantargia’s Q2 report covers one of the most eventful periods in the company’s history. The company signed a major deal with Otsuka Pharmaceutical for CAN10, while TRIFOUR showed no improved ORR when nadunolimab was added to chemotherapy. With the USD33m upfront, however, the company is now in great shape and is reviewing the next steps for nadunolimab. In August, the board appointed a new CEO, Dr Hilde Steineger, effective from September.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/